Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1007 in Non-criteria Manifestations of APS
NCT02128269Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2014
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of olendalizumab in antiphospholipid syndrome (APS), sponsored by Alexion Pharmaceuticals. Started Apr 2014; status: terminated.
02
Drugs
olendalizumab
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on NCT02128269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02128269.